Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
Last trade$74.34
Day change+$0.70 (+0.95%)
Day range$72.39 – $74.38
Volume1,304,924
Market cap$35.38B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$35.38B
Price / earnings
80.4×
Price / book
1.81×
Price / sales
4.12×
EV / sales
4.47×
EV / EBITDA
36.01×
Profitability
Earnings per share
$0.92
Return on assets
1.59%
Return on equity
2.25%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.2×
Current ratio
2.16×
Quick ratio
1.31×
Cash ratio
0.44×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
—
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ALC, quarterly periods
Line item
Q2 FY2022 Jun 30, 2022
Q4 FY2021 Dec 31, 2021
Q3 FY2021 Sep 30, 2021
Q2 FY2021 Jun 30, 2021
Q1 FY2021 Mar 31, 2021
Q4 FY2020 Dec 31, 2020
Q3 FY2020 Sep 30, 2020
Q2 FY2020 Jun 30, 2020
Revenue
$2.22B
$2.15B
$2.1B
$2.11B
$1.93B
$1.94B
$1.84B
$1.21B
Cost of revenue
$1.01B
$943M
$907M
$890M
$899M
$1.07B
$990M
$869M
Gross profit
$1.2B
$1.21B
$1.2B
$1.22B
$1.03B
$875M
$848M
$345M
Selling, general and administrative
$803M
$813M
$779M
$785M
$699M
$737M
$685M
$595M
Research and development
$181M
$180M
$318M
$178M
$166M
$155M
$216M
$163M
Total operating expenses
$1B
$1.02B
$1.18B
$991M
$882M
$734M
$977M
$811M
Operating income
$200M
$182M
$20M
$229M
$149M
$141M
-$129M
-$466M
Interest expense
-$31M
-$28M
-$31M
-$30M
-$31M
-$31M
-$32M
-$30M
Income before taxes
$147M
$141M
-$23M
$191M
$109M
$104M
-$168M
-$502M
Income taxes
-$1M
$2M
-$25M
$40M
$25M
$9M
-$21M
-$80M
Net income
$148M
$139M
$2M
$151M
$84M
$95M
-$147M
-$422M
Net income attributable to common shareholders
$148M
$139M
$2M
$151M
$84M
$95M
-$147M
-$422M
EBITDA
$200M
$182M
$453M
$229M
$433M
$141M
$301M
-$67M
Basic earnings per share
$0.30
$0.29
$0.00
$0.31
$0.17
$0.19
-$0.30
-$0.86
Diluted earnings per share
$0.30
$0.28
$0.00
$0.31
$0.17
$0.19
-$0.30
-$0.86
Recent news
Company coverage with links to the original publishers.
Alcon reported Q3 2026 earnings with ~6% full-year net sales growth guidance and double-digit core EPS growth. The company is defending its premium intraocular lens market share against competitors through new products (Vivity Pro, TruPlus), expanding UNITY surgical equipment placements to 40% of U.S. teaching hospitals, and acquiring Neurotech Pharmaceuticals for retinal disease treatment with peak sales potential of $250-400 million. Management emphasized outpacing the 3% baseline eye care market growth through operational efficiency and margin expansion.
Alcon Inc. (ALC) reported Q3 2026 core EPS of 91 cents, beating estimates by 2.3%, but net sales of $2.72 billion missed consensus by 0.6%. While Vision Care and Equipment segments showed strength, Implantables sales declined 2% due to competitive pressures. The company narrowed its 2026 guidance, expecting 6% constant-currency net sales growth and 12-14% core EPS growth, which weighed on investor sentiment.
Alcon reported $2.72 billion in revenue for Q3 2026, up 4.9% year-over-year, slightly missing the consensus estimate of $2.73 billion. EPS of $0.91 exceeded expectations of $0.89. The company showed strong growth in Vision Care (+5.8%) and Equipment/other segments (+10.7%), but faced headwinds in Implantables (-2.3%) and Other revenues (-20%). The stock has outperformed the broader market with a +16.8% return over the past month.
Alcon (ALC) shares surged 6.8% to $77.31 on investor optimism ahead of its third quarter 2026 earnings release on November 11. The company is expected to report EPS of $0.89 (up 12.7% YoY) and revenues of $2.73 billion (up 5.6% YoY). However, with unchanged earnings estimate revisions over the past 30 days, analysts caution that the stock may struggle to maintain momentum without further positive estimate revisions. NeuroPace (NPCE), a peer in the medical instruments industry, also gained 8.4% but remains down 2.8% over the past month.
Wellcome Leap, a nonprofit founded by the Wellcome Trust to accelerate health breakthroughs, announced that John Young (former Pfizer Chief Business Officer) and Thomas Glanzmann (former Grifols CEO) have joined its Board of Directors. Both bring decades of experience in global healthcare leadership, pharmaceutical operations, and business development.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
May 6, 2026
CHF 0.28
May 7, 2026
recurring
May 14, 2025
CHF 0.28
May 15, 2025
recurring
May 14, 2024
CHF 0.24
May 16, 2024
recurring
May 10, 2023
CHF 0.21
May 12, 2023
recurring
May 3, 2022
CHF 0.20
May 5, 2022
recurring
Stock splits
Historical share-structure events and their execution dates.